Test Overview
Clinical Utility
Rufinamide is an antiepileptic indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children and adults. As multiple antiepileptics may be administered, it may be important to (1) optimize therapy, (2) monitor compliance, and (3) avoid toxicity.
Source: https://testdirectory.questdiagnostics.com/test/test-detail/16296/rufinamide?p=r&q=rufinamide&cc=MASTER; Accessed 10-Jul-2019.
Method
Chromatography/MS
Result Included
Rufinamide
Specimen
Specimen Type
Avoid gel separator tubesSerum
Plasma (EDTA)
Volume
Sample Volume
1 mL
Minimum Volume
0.5 mL
Specimen Comment
Avoid gel separator tubes.
Collection & Handling
Collection Instructions
Collect trough specimen within 1 hour prior to next dose.
Handling Information
Store and send cold.
Stability
| Ambient | Refrigerated | Frozen |
|---|---|---|
| 7 days | 30 days | 30 days |
Rejection Criteria
| Criteria | Specification |
|---|---|
| Specimen | Gel-separator |
Performance & Interpretation
Turnaround Time
7 days
Results
Name
Units
Reference Range
Conversion
-
Rufinamideµg/mLTherapeutic range not determined
Comment
Maintenance therapy with 45 mg/kg (approximately 1600 mg) daily Rufinamide resulted in plasma concentrations ranging from 5.0 - 55.0 µg/mL
Referral Location
Out-of-Country
Test Version
Last Updated
2019-09-30